Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Corren

Showing results (121-130 of 141) with videos related to

Pageof 15
Sort By:
Journal of Asthma and Allergy|March 14, 2023
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen SensitizationJonathan Corren, David J Jackson, Thomas B Casale, et al.
The Lancet. Respiratory Medicine|October 7, 2021
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm studyAndrew Menzies-Gow, Mark Gurnell, Liam G Heaney, et al.
The European Respiratory Journal|July 27, 2022
Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE studyAndrew Menzies-Gow, Mark Gurnell, Liam G Heaney, et al.
Thorax|May 24, 2015
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studiesNicola A Hanania, Michael Noonan, Jonathan Corren, et al.
Allergy|January 27, 2024
Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapyMatthew F Wipperman, Kaitlyn M Gayvert, Amanda Atanasio, et al.
American Journal of Clinical Dermatology|January 22, 2021
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or AsthmaAshish Bansal, Eric L Simpson, Amy S Paller, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 7, 2022
Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United StatesMoisés A Calderon, Thomas B Casale, Harold S Nelson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 16, 2021
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Lisa A Beck, Lawrence Sher, et al.
The Journal of Allergy and Clinical Immunology|October 12, 2022
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trialJonathan Corren, David Larson, Matthew C Altman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 16, 2019
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic AsthmaJonathan Corren, Mario Castro, Thomas O'Riordan, et al.
Pageof 15

Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Journal of Asthma and Allergy|March 14, 2023
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen SensitizationJonathan Corren, David J Jackson, Thomas B Casale, et al.
The Lancet. Respiratory Medicine|October 7, 2021
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm studyAndrew Menzies-Gow, Mark Gurnell, Liam G Heaney, et al.
The European Respiratory Journal|July 27, 2022
Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE studyAndrew Menzies-Gow, Mark Gurnell, Liam G Heaney, et al.
Thorax|May 24, 2015
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studiesNicola A Hanania, Michael Noonan, Jonathan Corren, et al.
Allergy|January 27, 2024
Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapyMatthew F Wipperman, Kaitlyn M Gayvert, Amanda Atanasio, et al.
American Journal of Clinical Dermatology|January 22, 2021
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or AsthmaAshish Bansal, Eric L Simpson, Amy S Paller, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 7, 2022
Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United StatesMoisés A Calderon, Thomas B Casale, Harold S Nelson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 16, 2021
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Lisa A Beck, Lawrence Sher, et al.
The Journal of Allergy and Clinical Immunology|October 12, 2022
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trialJonathan Corren, David Larson, Matthew C Altman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 16, 2019
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic AsthmaJonathan Corren, Mario Castro, Thomas O'Riordan, et al.
Pageof 15